Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Michael Scott

Nurse Practitioner, Psychiatric/Mental Health Manchester, NH Nurse Practitioner

NPI 1063058931 CMS profile 10479910

2 Wall St Ste 300, Manchester, NH 03101

Open in the dashboard

General payments

$48,165

199 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Scott of Manchester, NH is reported in the CMS Open Payments database as having received $48,165 across 199 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $47,000 145
2024 General $468 26
2023 General $343 16
2022 General $354 12

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Scott
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Michael Scott were reported at $47,000. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Michael Scott Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $166 $54–$482 $132
2022 $354 $195 $66–$559 $149
2023 $343 $233 $82–$673 $160
2024 $468 $236 $84–$688 $164
2025 $47,000 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. Neurocrine Biosciences, Inc. $30,049 63 payments
  2. AbbVie, Inc. $16,832 86 payments
  3. Axsome Therapeutics, Inc. $501 15 payments
  4. Vanda Pharmaceuticals Inc. $277 14 payments
  5. Otsuka America Pharmaceutical, Inc. $178 9 payments
  6. Lundbeck LLC $136 7 payments
  7. Biogen, Inc. $100 1 payment
  8. E.R. Squibb & Sons, L.L.C. $51 2 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $41 2 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $31,001 16 payments
  2. Consulting Fee $6,750 1 payment
  3. Travel and Lodging $6,656 45 payments
  4. Food and Beverage $3,759 137 payments
Products named General payments · program years 2022–2025
  1. INGREZZA $29,956 62 payments
  2. VRAYLAR Neuroscience $16,238 55 payments
  3. VRAYLAR Neuroscience $594 31 payments
  4. Auvelity $501 15 payments
  5. FANAPT $277 14 payments
  6. HETLIOZ $195 10 payments
  7. REXULTI Psychiatry $178 9 payments
  8. REXULTI Psychiatry $136 7 payments
  9. Zurzuvae $100 1 payment
  10. COBENFY $51 2 payments
  11. Other $61 3 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

1,115

Median for Nurse Practitioner: 389

Drug cost

$72,440

Median for Nurse Practitioner: $21,885

Branded share of claims

14.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 17 $25,439
Rexulti Brexpiprazole Brand 11 $17,711
Lurasidone Hcl Generic 12 $3,690
Ziprasidone Hcl Generic 34 $2,998
Aripiprazole Generic 38 $2,968
Sertraline Hcl Generic 123 $2,669
Paliperidone Er Paliperidone Brand 14 $1,527
Bupropion Hcl Sr Bupropion Hcl Brand 39 $1,321
Clozapine Generic 11 $1,260
Bupropion Xl Bupropion Hcl Brand 40 $1,182

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 7 billing codes

Paid by Medicare

$9,354

Medicare's payments for the services billed

Medicare patients

44

Average age 55

Services billed

137

29 women, 15 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 45%
Depression 43%
Arthritis 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $199
$199 17 —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $96
  • Lundbeck LLC $20
$116 11 —
INGREZZA
  • Neurocrine Biosciences, Inc. $98
$98 — —
TRINTELLIX
  • Takeda Pharmaceuticals U.S.A., Inc. $25
$25 — —
FANAPT
  • Vanda Pharmaceuticals Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

199 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in New Hampshire

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record